成都圣诺生物科技股份有限公司发布2025年年度权益分派实施公告
关键要点摘要
- 每股现金红利0.32元，每股转增0.4股，分红与股本扩张同步进行。
- 分配基准日股本为157,385,978股，分红后总股本将增加至220,340,369股。
- 股权登记日为2026年6月4日，除权（息）日、现金红利发放日及新增股份上市日均为2026年6月5日。
- 公司首发战略配售股份已全部上市流通，不涉及差异化分红送转。
- 本次权益分派将对2023年限制性股票激励计划的授予价格进行相应调整，或对公司股价产生影响。
- 实施送转股后，2025年度每股收益将摊薄至0.7167元。
详细内容
成都圣诺生物科技股份有限公司（688117，简称“圣诺生物”）于2026年6月1日发布了2025年度权益分派实施公告。公司董事会及全体董事承诺公告内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。
本次权益分派方案已于2026年5月15日经2025年年度股东大会审议通过。分红及转增基准为实施前公司总股本157,385,978股，每股派发现金红利0.32元（含税），并以资本公积金每股转增0.4股。此次权益分派后，公司总股本将增至220,340,369股，合计派发现金红利50,363,512.96元，转增股份62,954,391股。
关键日期如下：
- 股权登记日：2026年6月4日
- 除权（息）日、新增股份上市日、现金红利发放日：2026年6月5日
权益分派对象为截至股权登记日收市后，在中国证券登记结算有限责任公司上海分公司登记在册的全体股东。红利和转增股份均由结算公司直接派发或划入账户，无需额外操作。
税收政策说明
- 自然人股东及证券投资基金持有“无限售条件流通股”，持股超过1年，股息红利所得暂免征收个人所得税。持股1年以内的，暂不扣税，待转让时计算与扣缴。具体税负：持股1个月以内20%，1个月至1年10%，1年以上免税。
- QFII（合格境外机构投资者）由公司代扣代缴10%企业所得税，税后每股现金红利0.288元。
- 香港市场投资者（沪港通）税率同为10%，税后分红0.288元。如享受更低协定税率可申请退税。
- 其他机构及法人股东需自行申报企业所得税，公司发放税前0.32元。
- 本次转增股本来源为资本公积金，不涉及征税。
股本结构变化
- 本次权益分派及转增后，所有股份均为无限售条件流通股，公司首发战略配售股份已全部上市流通。
- 本次权益分派实施后，2023年限制性股票激励计划的首次及预留授予价格将进行调整，具体内容待后续公告。
- 实施送转股后，按新总股本220,340,369股计算，2025年度每股收益摊薄至0.7167元。
投资者须知与风险提示
- 本次权益分派将显著增加公司流通股本，对公司每股收益产生摊薄效应，或对股价造成一定影响，投资者需密切关注。
- 红利及转增股份到账后，投资者需注意其持股数量变化及税收政策，特别是短期持有者的税负变化。
- 公司将根据权益分派完成情况，调整限制性股票激励计划价格，或涉及较大市值变动。
- 如有疑问可咨询公司证券部，电话：028-88203615，邮箱：[email protected]。
总结
本次公告涉及现金分红与转增股本，双重利好，但由于流通股本显著扩张，每股收益将相应摊薄，投资者应关注分红后公司估值变化及激励计划调整对二级市场的影响。由于分红派息和股本扩张通常会对公司股价产生波动，属重大公告，建议投资者审慎决策。
免责声明：本文内容仅供参考，不构成任何投资建议。投资有风险，决策需谨慎。请投资者根据自身情况理性判断。
Chengdu Sino Biological Technology Co., Ltd. Announces 2025 Annual Rights Distribution Plan
Key Highlights
- Cash dividend of RMB 0.32 per share and a bonus issue of 0.4 new shares per share—simultaneous cash payout and capital expansion.
- Based on a record date share capital of 157,385,978 shares, the total share capital will increase to 220,340,369 shares after the distribution.
- Record date: June 4, 2026; Ex-dividend date, bonus share listing, and cash dividend payout date: June 5, 2026.
- All initial strategic placement shares have become tradable; no differentiated dividend or bonus issue applies.
- This distribution will trigger an adjustment to the grant price in the company’s 2023 Restricted Stock Incentive Plan, which may affect share price.
- Post-distribution, 2025 diluted EPS will be RMB 0.7167 per share.
Detailed Information
Chengdu Sino Biological Technology Co., Ltd. (688117, “Sino Biological”) released its 2025 annual equity distribution implementation announcement on June 1, 2026. The board guarantees the announcement is true, accurate, and complete.
The rights distribution plan was approved at the 2025 AGM on May 15, 2026. The plan is based on the total share capital before implementation (157,385,978 shares). Each share will receive a cash dividend of RMB 0.32 (before tax), and 0.4 new shares per share from capital reserve. After the distribution, total share capital will rise to 220,340,369 shares, with total cash dividend payout of RMB 50,363,512.96 and 62,954,391 new shares issued.
Key Dates:
- Record date: June 4, 2026
- Ex-dividend date, bonus share listing, and dividend payment: June 5, 2026
All shareholders registered by the close of trading on the record date with China Securities Depository and Clearing Corporation (Shanghai branch) will be eligible. Both the dividend and bonus shares will be distributed directly through the clearing system.
Tax Policy Details
- For individual shareholders and securities funds holding tradable shares: holding period over 1 year, dividend tax-exempt; holding within 1 year, no tax withheld at payout, but taxed at transfer according to the actual holding period (20% for ≤1 month, 10% for >1 month to 1 year, tax-free for >1 year).
- QFII (Qualified Foreign Institutional Investors): Company withholds 10% corporate income tax, net dividend is RMB 0.288 per share.
- Hong Kong investors (via Stock Connect): Same 10% withholding, net RMB 0.288 per share. Lower tax rates under treaties can be applied for via tax authority.
- Other institutional and corporate shareholders: Responsible for their own corporate income tax, company pays pre-tax RMB 0.32 per share.
- The bonus share issue comes from capital reserve and is not taxable.
Share Capital Structure Change
- All shares will be tradable after this distribution; all initial strategic allotment shares have become tradable.
- The company will adjust the grant price for its 2023 Restricted Stock Incentive Plan after this distribution, potentially impacting market value and share price.
- Post-distribution, diluted EPS for 2025 will be RMB 0.7167 based on the new total share capital.
Investor Reminders and Risks
- This equity distribution will significantly increase the number of floated shares, diluting EPS and possibly impacting share price—investors should monitor closely.
- After distribution, investors should note the change in their shareholding and applicable tax policy, especially for those with short-term holdings.
- Share incentive plan price adjustment may result in noticeable changes in company market cap.
- For inquiries, contact the company’s securities department at 028-88203615 or email [email protected].
Summary
This announcement is significant due to the simultaneous cash dividend and bonus share issue, which may affect the stock price through EPS dilution and changes to the restricted stock plan. Investors are advised to pay close attention to post-distribution valuation and forthcoming related disclosures.
Disclaimer: The above content is for reference only and does not constitute investment advice. Investment carries risk; please make decisions carefully based on your own circumstances.
